

FORM PTO-1449 (Modified)			Attorney Docket No.:		Application No.:	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Min Michael He et al:			
			Filing Date:		Group:	
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
___ AA						
___ AB						
___ AC						
___ AD						
___ AE						
___ AF						
___ AG						
___ AH						
___ AI						
___ AJ						
___ AK						
___ AL						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
___ <u>KG</u> AM	DE 197 32 855 A1	0218/99	Indena	A61K	35/78	No
___ <u>KG</u> AN	DE 197 32 866 A1	02/18/99	Indena	A61K	3578	No
___ AO						
___ AP						
___ AQ						
___ AR						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
___ <u>KG</u> AS	Derwent Publication Ltd., Lodon, GB, Class A96, AN 1997-534403 XP002151122					
___ AT						
___ AU						
___ AV						
___ AW						
EXAMINER		DATE CONSIDERED				
<u>Kurt M. G.</u>		6.7.04				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Attorney Docket No.:		Application No.:	
			Applicant: Min Michael He, Fang-yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang and Ezio Bombardelli			
			Filing Date:		Group:	
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>K6</u> AA	5,830,887	11/03/98	Kelly	514	182	
<u>1</u> AB	5,674,548	10/07/97	Nakamura et.al.	426	598	
<u>1</u> AC	5,855,892	01/05/99	Potter et. al.	424	195.1	
<u>K6</u> AD	5,858,449	01/12/99	Crank et. al.	426	656	
<u>1</u> AE						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<u>1</u> AF						
<u>1</u> AG						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<u>K6</u> AH	Anthony, et. al.: "Effects of soy isoflavones on atherosclerosis: potential mechanisms ¹⁻³ " <i>Am J Clin Nutr</i> 1998; (68) (suppl): 1390S-3S					
<u>1</u> AI	Greg Peterson and Stephen Barnes: "Genistein inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and the multi-drug resistance gene" <i>Biochemical and Biophysical Research Communications</i> 08/30/91 Vol. 179, No. 1, pages (661-667)					
<u>1</u> AJ	Lee-Jane W Lu and Karl E. Anderson: "Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans ¹⁻³ " <i>Am J Clin Nutr</i> 1998; (68) (suppl): 1500S-4S					
<u>1</u> AK	Zhang, et. al.: "Daidzein and Genistein Glucuronides in Vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations ^{1,2,3} " <i>J. Nutr.</i> 129: 399-405 (1999)					
<u>1</u> AL	Mark Messina and Stephen Barnes: "The Role of Soy Products in Reducing Risk of Cancer ¹ " <i>Journal of the National Cancer Institute</i> Vol. 83, No. 8, 541-546 (4/17/91)					
<u>1</u> AM	Greg Peterson and Stephen Barnes: "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation" <i>The Prostate</i> 22: 335-345 (1993)					
<u>1</u> AN	Charland et. al.: "The effects of a soybean extract on tumor growth and metastasis" <i>International Journal of Molecular Medicine</i> 2: 225-228 (1998)					
<u>K6</u> AO	Kathleen A. Head, N.D. "Ipriflavone: An Important Bone-Building Isoflavone" <i>Alternative Medicine Review</i> Vol. 4, No. 1, 10-22 (1999)					
<u>1</u> AP						
<u>1</u> AQ						
EXAMINER <u>Kurt M. C.</u> DATE CONSIDERED <u>6-7-01</u>						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.